Overall, these results suggest that the prevalence of pre-existing antibody responses to Sa Cas9 and Sp Cas9 is relatively high in both non-CF and CF populations, consistent with previous findings reported in a cohort of healthy humans.9 The gene discussed is TFF2; the disease is cystic fibrosis.